Bigler Marius R, Stark Anselm W, Shiri Isaac, Illi Joel, Siepe Matthias, Caobelli Federico, Giannopoulos Andreas A, Buechel Ronny R, Haeberlin Andreas, Obrist Dominik, Räber Lorenz, Gräni Christoph
Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Centre for Congenital Heart Disease, Department of Cardiovascular Surgery, Inselspital, Bern, Switzerland.
Contemp Clin Trials Commun. 2024 Nov 19;42:101394. doi: 10.1016/j.conctc.2024.101394. eCollection 2024 Dec.
Anomalous aortic origin of a coronary artery (AAOCA) is a rare congenital heart disease, potentially leading to myocardial ischemia and adverse cardiac events. As the sole presence of AAOCA does not always imply a revascularization, a detailed anatomical and functional analysis is crucial for clinical decision-making. Currently, invasive coronary angiography is the gold-standard method for a thorough hemodynamic assessment of AAOCA. However, due to its invasive nature, the development of noninvasive diagnostic alternatives is desired.
In the NARCO trial, patients with AAOCA will undergo coronary computed tomography angiography (CCTA) to assess anatomical high-risk features followed by a vessel-based (i.e. invasive measurement with fractional flow reserve and intravascular imaging under a dobutamine-volume challenge) and a myocardium-based (i.e. nuclear imaging) ischemia testing. Comparison of noninvasive and invasive imaging will be performed. Additionally, explorative analysis of post-processing advanced computational fluid dynamics (CFD) and 3D printing will be performed to unravel the pathophysiologic mechanism of myocardial ischemia in AAOCA.
Our primary aim is to define characteristics of anatomical high-risk features (using CCTA) to rule out noninvasively hemodynamically relevant anomalous vessels in AAOCA patients. The secondary aim is to investigate the underlying pathophysiology of AAOCA-related hemodynamic relevance using advanced techniques such as CFD and 3D printing.
The NARCO trial will help to optimize AAOCA patient selection for revascularization by improving risk stratification and ruling out hemodynamic relevance noninvasively and, therefore, preventing unnecessary downstream testing and/or costly interventions in patients with AAOCA.
冠状动脉异常起源(AAOCA)是一种罕见的先天性心脏病,可能导致心肌缺血和不良心脏事件。由于AAOCA单独存在时并不总是意味着需要血运重建,详细的解剖和功能分析对于临床决策至关重要。目前,有创冠状动脉造影是对AAOCA进行全面血流动力学评估的金标准方法。然而,由于其有创性,人们期望开发无创诊断替代方法。
在NARCO试验中,AAOCA患者将接受冠状动脉计算机断层扫描血管造影(CCTA)以评估解剖学高危特征,随后进行基于血管的(即使用血流储备分数进行有创测量并在多巴酚丁胺-容量负荷下进行血管内成像)和基于心肌的(即核成像)缺血测试。将对无创和有创成像进行比较。此外,还将对后处理高级计算流体动力学(CFD)和3D打印进行探索性分析,以阐明AAOCA中心肌缺血的病理生理机制。
我们的主要目的是定义解剖学高危特征的特点(使用CCTA),以无创地排除AAOCA患者中血流动力学相关的异常血管。次要目的是使用CFD和3D打印等先进技术研究AAOCA相关血流动力学相关性的潜在病理生理学。
NARCO试验将有助于通过改善风险分层和无创地排除血流动力学相关性来优化AAOCA患者血运重建的选择,从而防止对AAOCA患者进行不必要的下游检查和/或昂贵的干预。